**Abstract**

**Background:** The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab. We report findings in high-risk patients (FL International Prognostic Index (FLIPI) score ≥3, and high tumor burden by modified Groupe d’Etude des Lymphomas Folliculaires [GELF] criteria).

**Methods:** Patients aged ≥18 years with grade 1/2 FL, ≥1 measurable lesion, and documented relapse or progression following prior therapy, rituximab-naïve or rituximab-sensitive, were enrolled at 164 centers in 29 countries across Europe, the Americas, and Asia-Pacific. Patients were randomized (1:1) to five 5-week cycles of bortezomib-rituximab (bortezomib 1.6 mg/m², days 1, 8, 15, and 22, all cycles; rituximab 375 mg/m², days 1, 8, 15, and 22, cycle 1, and day 1, cycles 2–5; N=336) or rituximab alone (N=340). Randomization was stratified by FLIPI score, prior rituximab, time since last dose of anti-lymphoma therapy, and geographical region. The primary endpoint of the study was PFS.

**Results:** 103 bortezomib-rituximab and 98 rituximab patients had high-risk FL. The ORR was 59% versus 37% (p=0.002), the CR/CRu rate was 13% versus 6% (p=0.145), and the durable response rate was 45% versus 26% (p=0.008) with bortezomib-rituximab versus rituximab. Median PFS was 9.5 versus 6.7 months (hazard ratio [HR] 0.667, p=0.012) with bortezomib-rituximab versus rituximab; median time to progression was 10.9 versus 6.8 months (HR 0.656, p=0.009); median time to next anti-lymphoma treatment was 14.8 versus 9.1 months (HR 0.762, p=0.103); and the 1-year Overall Survival rate was 83.1% versus 76.6%. Overall, 51% of bortezomib-rituximab and 32% of rituximab patients reported grade ≥3 adverse events, including neutropenia (18%, 6%), anemia (4%, 5%), diarrhea (8%, 0%), thrombocytopenia (5%, 2%), and sensory neuropathy (1%, 0%).

**Conclusions:** High-risk FL patients treated with bortezomib-rituximab had significantly higher ORR and longer PFS than patients receiving rituximab alone, with greater clinical benefit than in the overall study population; additional toxicity was acceptable and did not affect treatment feasibility.

**Trial registration:** The phase 3 LYM3001 trial is registered with ClinicalTrials.gov, with the identifier NCT00312845.

**Keywords:** Bortezomib, Follicular, High risk, Lymphoma, Rituximab
Background

Follicular lymphoma (FL) is an incurable, indolent non-Hodgkin’s lymphoma (NHL) subtype that follows a relapsing course [1,2]. Although the introduction of new therapies and treatment approaches over the past couple of decades has improved progression-free survival (PFS) [3] and overall survival (OS) [4,5], prognosis differs significantly between patients according to multiple demographic and disease-related characteristics [5-10]. Adverse prognostic factors in FL include a high (≥3) FL International Prognostic Index (FLIPI) score, representing patients aged >60 years, and/or with stage III–IV disease, anemia, >4 involved nodal areas, and/or elevated lactate dehydrogenase (LDH) [7,10,11], which has been validated in the first-line setting [11] and shown to have prognostic value at first relapse [10]. In addition, another indicator of poor prognosis is a high tumor burden by modified Groupe d’Etude des Lymphomas Folliculaires (GELF) criteria [12], which includes involvement of ≥3 nodal sites of ≥3 cm diameter, any nodal/extranodal tumor mass of ≥7 cm diameter, splenomegaly, pleural effusion or peritoneal ascites, leukocytes <1.0 x 10^9/L, or platelets <100 x 10^9/L [12,13].

Patients with high-risk FL typically have a poor prognosis, including a higher probability of relapse and lower survival rates [7,10,11], and need better treatment options [10,14,15]. These patients may particularly benefit from novel, active regimens [10]. Rituximab is widely used in previously untreated and relapsed FL [16], having been shown to enhance the efficacy of chemotherapeutic regimens [17-19] and to improve PFS when used as maintenance therapy [3,20]. The proteasome inhibitor bortezomib has shown single-agent activity in heavily pretreated indolent lymphoma patients, with response rates of up to 50% [21-23], and bortezomib plus rituximab has been shown to be active and generally well tolerated in phase 2 studies in FL and other NHL subtypes [24-27].

The randomized, multicenter, international phase 3 LYM3001 trial compared bortezomib plus rituximab with rituximab alone in 676 patients with relapsed, rituximab-naïve or rituximab-sensitive FL [28]. Results from the overall study population showed that the addition of bortezomib resulted in prolonged PFS (primary endpoint; median 12.8 vs. 11.0 months, hazard ratio [HR] 0.822; P=0.039), a higher overall response rate (ORR; 63% vs. 49%, P=0.001), a higher complete response (CR)/unconfirmed CR (CRu) rate (25% vs. 18%, P=0.035), and more durable responses. In this ad-hoc subgroup analysis of LYM3001, we report the activity and safety of rituximab ± bortezomib in patients with high-risk disease, defining ‘high-risk’ patients as those having both a high (≥3) FLIPI score and high tumor burden by modified GELF criteria [12], both of which were independent pre-defined subgroups.

Results

Patients

In the overall study population, 139 patients in the bortezomib-rituximab arm and 140 patients in the rituximab arm had high FLIPI score (≥3), and 185 and 179 patients, respectively, had high tumor burden by modified GELF criteria [12]. Of these patients, 103 in the bortezomib-rituximab arm and 98 in the rituximab arm had high-risk FL per the definition for this subgroup analysis (both FLIPI score ≥3 and high tumor burden by modified GELF criteria [12]). High-risk patient demographics and baseline disease characteristics in the intention-to-treat (ITT) population are shown in Table 1. Demographics were consistent with those in the overall study population; disease characteristics reflected the high-risk nature of the patients compared with the overall study population [28]. Disease characteristics and prior therapy exposure were generally balanced between arms except for Ann Arbor staging and sex, with higher proportions of patients with stage IV disease and males in the bortezomib-rituximab arm.

Patient disposition and treatment exposure in the safety population are shown in Table 2. One patient with high-risk FL in the bortezomib-rituximab arm was not treated and was excluded from the safety population. Treatment exposure was generally comparable with that in the overall study population [28], with patients in both arms receiving a median of five cycles. However, slightly lower proportions of patients in each arm completed all five cycles in this high-risk population (64% and 53% in the bortezomib-rituximab and rituximab arms, respectively) compared with in the overall population (72% and 71%, respectively) [28], reflecting that these patients were more challenging to treat. Among the reasons for discontinuing treatment prior to completing five cycles, disease progression was less common (25% vs. 39%) but adverse events (AEs) more common (8% vs. 2%) in patients receiving bortezomib-rituximab versus rituximab.

Efficacy

Bortezomib-rituximab resulted in a higher ORR and CR/CRu rate than rituximab in patients with high-risk FL (Table 3). Similarly, the rate of durable (≥6 months) response was higher, and median duration of response (DOR) in patients with CR/CRu was prolonged with bortezomib-rituximab, although median DOR in all responding patients appeared somewhat shorter.

In patients with high FLIPI score (≥3) regardless of tumor burden, ORR was 64% versus 45% (odds ratio 0.459 [95% confidence interval (CI) 0.279, 0.756],


p=0.002), CR/CRu rate was 20% versus 10% (odds ratio 0.446 [95% CI 0.217, 0.916], p=0.026), and durable response rate was 50% versus 32% (odds ratio 0.459 [95% CI 0.277, 0.761], p=0.002) with bortezomib-rituximab versus rituximab in patients with high tumor burden regardless of FLIPI score, ORR was 60% versus 41% (odds ratio 0.468 [95% CI 0.306, 0.717], p<0.001), CR/CRu rate was 19% versus 10% (odds ratio 0.476 [95% CI 0.254, 0.891], p=0.019), and durable response rate was 45% versus 32% (odds ratio 0.581 [95% CI 0.377, 0.897], p=0.014) with bortezomib-rituximab versus rituximab.

Table 1 Baseline characteristics of LYM3001 patients with high-risk FL (ITT population)

|                                | Bortezomib-rituximab (N=103) | Rituximab (N=98) |
|--------------------------------|-------------------------------|-----------------|
| Median age, years (range)      | 61 (38–83)                    | 60 (21–84)      |
| Aged >65 years, n (%)          | 31 (30)                       | 25 (26)         |
| Male, n (%)                    | 53 (51)                       | 42 (43)         |
| Race, n (%)                    |                               |                 |
| White                          | 78 (76)                       | 65 (66)         |
| Asian                          | 20 (19)                       | 29 (30)         |
| Other                          | 5 (5)                         | 4 (4)           |
| Region, n (%)                  |                               |                 |
| USA and Canada                 | 8 (8)                         | 10 (10)         |
| European Union                 | 34 (33)                       | 28 (29)         |
| Rest of the World*             | 61 (59)                       | 60 (61)         |
| ECOG performance status, n (%) |                               |                 |
| 0                              | 36 (35)                       | 35 (36)         |
| 1                              | 56 (54)                       | 52 (53)         |
| 2                              | 11 (11)                       | 11 (11)         |
| Ann Arbor Stage, n (%)         |                               |                 |
| II                             | 0                             | 1 (1)           |
| III                            | 36 (35)                       | 45 (46)         |
| IV                             | 67 (65)                       | 52 (53)         |
| High tumor burden by modified GELF criteria [12], n (%) | 103 (100) | 98 (100) |
| High (2–3) FLIPI score [7], n (%) | 103 (100) | 98 (100) |
| Elevated serum LDH, n (%)      | 70 (68)                       | 61 (62)         |
| Median time from initial diagnosis, months (range) | 35.8 (2–233) | 38.5 (1–197) |
| Number of prior lines of therapy, n (%) |                         |                 |
| 1                              | 43 (42)                       | 35 (36)         |
| 2                              | 25 (24)                       | 31 (32)         |
| ≥3                             | 35 (34)                       | 32 (32)         |
| Common prior therapies, n (%)  |                               |                 |
| CHOP                           | 41 (40)                       | 40 (41)         |
| CVP                            | 35 (34)                       | 23 (23)         |
| Single-agent rituximab         | 17 (17)                       | 13 (13)         |
| Chlorambucil-prednisone        | 9 (9)                         | 14 (14)         |
| R-CHOP                         | 10 (10)                       | 12 (12)         |
| R-CVP                          | 9 (9)                         | 12 (12)         |
| Single-agent chlorambucil      | 10 (10)                       | 10 (10)         |
| Any prior rituximab therapy, n (%) | 40 (39)             | 40 (41)         |
| >1 year since last FL treatment, n (%) | 53 (51)             | 48 (49)         |
| Creatinine clearance >30–60 mL/min, n (%) | 18 (17)             | 24 (24)         |

*Including 21%/12% from Russia, 10%/14% from People’s Republic of China, 9%/14% from India, and 9%/11% from Brazil in the bortezomib-rituximab/rituximab arms.

ECOG, Eastern Cooperative Oncology Group; GELF, Groupe d’Etude des Lymphomas Folliculaires; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.
With a median follow-up of 35.2 months in each arm in the ITT population of high-risk patients, median PFS was 9.5 months in the bortezomib-rituximab arm versus 6.7 months in the rituximab arm (HR 0.667, p=0.012) (Figure 1A). Other outcomes were also longer with bortezomib-rituximab versus rituximab, including: time to progression (TTP; median 10.9 [95% CI 8.6, 11.8] vs. 6.8 [95% CI 4.5, 9.1] months; HR 0.656, p=0.009); time to next anti-lymphoma treatment (TTNT; median 14.8 vs. 9.1 months; HR 0.762, p=0.103) (Figure 1B); and treatment-free interval (TFI; median 9.2 [95% CI 6.2, 13.0] vs. 5.6 [95% CI 2.6, 10.4] months).

In patients with high FLIPI score (≥3) regardless of tumor burden, median PFS was 11.4 versus 7.9 months (HR 0.707, p=0.013), median TTP was 11.5 versus 9.0 months (HR 0.688, p=0.009), median TTNT was 17.1 versus 14.4 months (HR 0.760, p=0.067), and median TFI was 12.8 versus 9.8 months (HR 0.788, p=0.110) with bortezomib-rituximab versus rituximab; in patients with high tumor burden regardless of FLIPI score, respective rates in patients with high tumor burden regardless of FLIPI score were 87.2% versus 84.3% (HR 0.981, p=0.919). The 1-year OS rate was 83.1% (95% CI 75.8, 90.4) versus 76.6% (95% CI 68.0, 85.2) (HR 0.907, p=0.657) with bortezomib-rituximab and rituximab, respectively. Median OS was 37.8 (95% CI 31.9, not estimable) versus 41.5 (95% CI 25.0, not estimable) months in patients with high FLIPI score (≥3) regardless of tumor burden, and 37.8 (95% CI 31.9, not estimable) versus 41.5 (95% CI 25.0, not estimable) months in patients with high tumor burden regardless of FLIPI score.

### Safety

The safety profiles of bortezomib-rituximab and rituximab in patients with high-risk FL are summarized in Table 4. The rates of grade ≥3 AEs (51% vs. 32%), serious AEs (22% vs. 16%), and AEs leading to treatment discontinuation (1% vs. 1%) were lower with bortezomib-rituximab versus rituximab, respectively. The safety profiles are presented in Table 4.

### Table 2 Patient disposition and treatment exposure (safety population)

|                         | Bortezomib-rituximab (N=102) | Rituximab (N=98) |
|-------------------------|-------------------------------|-----------------|
| Median number of cycles, n (range) | 5 (1–5)                     | 5 (1–5) | 51% vs. 32% |
| Median treatment duration, weeks (range) | 25 (5–33)                 | 25 (5–27) | 0.013 |
| Patients completing all 5 cycles, n (%) | 65 (64)                    | 52 (53) |
| Patients discontinuing prior to completing 5 cycles, n (%), due to: | 37 (36)                    | 46 (47) |
| Disease progression | 26 (25)                      | 38 (39) |
| AEs | 8 (8)                        | 2 (2) |
| Treatment-related | 6 (6)                        | 0 |
| Death | 1 (1)                       | 1 (1) |
| Patient choice | 2 (2)                        | 4 (4) |
| Other reasons | 0                             | 1 (1) |
| Mean rituximab relative dose intensity, % | 98                           | 96 |
| Mean bortezomib relative dose intensity, % | 90                           | NA |

### Table 3 Best response to treatment and durability of response (response-evaluable population)

|                          | Bortezomib-rituximab (N=96) | Rituximab (N=95) | Odds ratio (95% CI) | P-value |
|--------------------------|---------------------------|-------------------|---------------------|---------|
| ORR, n (%)               | 57 (59)                   | 35 (37)           | 0.399(0.223, 0.715) | 0.002   |
| CR/CRu*, n (%)           | 12 (13)                   | 6 (6)             | 0.472(0.169, 1.314) | 0.145   |
| PR, n (%)                | 45 (47)                   | 29 (31)           | –                   | –       |
| Stable disease, n (%)    | 24 (25)                   | 32 (34)           | –                   | –       |
| Progressive disease, n (%) | 15 (16)               | 28 (29)           | –                   | –       |
| Durable (≥6 months) response, n (%) | 43 (45)             | 25 (26)           | 0.440(0.240, 0.809) | 0.008   |
| Median DOR, months       | 10.4                      | 12.1              | –                   | –       |
| Median DOR (CR/CRu*), months | 16.5                      | 10.5              | –                   | –       |

*Radiologic CR/CRu verified by bone marrow and lactate dehydrogenase.

CI, confidence interval; CR, complete response; CRu, unconfirmed CR; DOR, duration of response; ORR, overall response rate; PR, partial response.
discontinuation (8% vs. 2%) were higher with bortezomib-rituximab versus rituximab.

The most common AEs occurring at any grade in ≥15% of patients in either arm, or at grade ≥3 in ≥3% of patients in either arm, are also listed in Table 4. AEs were mostly mild or moderate (grade 1 or 2), with only neutropenia (18% and 6% in the bortezomib-rituximab and rituximab arms, respectively), infections (16%, 7%), anemia (4%, 5%), diarrhea (8%, 0%), and thrombocytopenia (5%, 2%) being reported at grade ≥3 in ≥5% patients in either arm. As shown in Table 4, peripheral sensory neuropathy was reported in 15 patients in the bortezomib-rituximab arm, and was grade 1 in 10 patients, grade 2 in four patients, and grade 3 in one patient. Additionally, one patient in this arm experienced grade 2 peripheral motor neuropathy. The only serious AEs reported in ≥2% of patients overall were pneumonia (5% in bortezomib-rituximab arm, 1% in rituximab arm), febrile neutropenia (1%, 3%), neutropenia (2%, 2%), pyrexia (3%, 1%), and diarrhea (2%, 1%).

Two deaths due to treatment-related AEs were reported in the bortezomib-rituximab arm. These were due to: septic shock (considered possibly related to both bortezomib and rituximab); and bilateral pneumonia (considered possibly related to bortezomib but not rituximab) as well as acute respiratory failure and acute cardiac failure, both considered unrelated to treatment [28]. In the rituximab arm, the one death due to an AE was due to meningitis (considered unrelated to treatment) [28].

Discussion

This ad-hoc subgroup analysis of the phase 3 LYM3001 study [28] of relapsed FL patients with the high-risk features of both high FLIPI score (≥3) and high tumor burden by modified GELF criteria [12] demonstrated a number of key efficacy findings. In particular, we showed that patients with high-risk FL treated with bortezomib-rituximab had significantly higher response rates and longer PFS than patients receiving rituximab alone. Furthermore, while overall median DOR appeared similar between arms, the durability of CR/CRu appeared enhanced with the addition of bortezomib in this high-risk patient population. The higher rate and durability of CR/CRu with bortezomib-rituximab is notable, as CR has been associated with improved outcomes in FL [29]. Additionally, the bortezomib-rituximab combination was associated with a significantly longer TTP, and a longer TTNT and associated TFI compared with rituximab alone. No significant difference was seen in OS between arms, as might be expected after a median follow-up of 3 years in a patient population with a typically indolent disease course and a reported median OS from diagnosis of up to approximately 14 years [4]. However, the 1-year OS rate appeared slightly higher in the bortezomib-rituximab arm, possibly due to an increased rate of progressive disease-related deaths in the rituximab arm during this period.

Notably, the consistent relative clinical benefit with bortezomib-rituximab versus rituximab in this subgroup of high-risk patients was greater than that seen in the overall study population [28], as indicated by HRs more in favor of bortezomib-rituximab. For example, the HR for PFS benefit with bortezomib-rituximab versus rituximab was 0.667 in these high-risk patients, compared with 0.882 in the overall study population [28]. Similarly, the odds ratios for ORR (0.399 vs. 0.569), CR/CRu rate (0.472 vs. 0.665), and durable (≥6 months) response rate (0.440 vs. 0.608), and the HRs for TTP (0.656 vs. 0.808), TTNT (0.762 vs. 0.799), and OS (0.907 vs. 0.971) indicated greater clinical benefit with bortezomib-rituximab versus rituximab in the high-risk subgroup versus the overall population. All these data suggest that the addition of bortezomib might thus provide greater benefit in high-risk FL patients.
tumor reduction and subsequent sustained clinical benefit in these patients who have a greater disease burden or more proliferative FL.

The patient population included in these analyses represented a true ‘high-risk’ subset of FL patients because they presented with both a high (≥3) FLIPI score and high tumor burden, both of which are factors that define cohorts of FL patients with disease that is high-risk in nature. The poor prognostic nature of each of these factors is supported by our efficacy analyses in the specific individual subsets with high FLIPI score or with high tumor burden, which demonstrated poorer outcomes compared with in the overall study population [28]; furthermore, our efficacy findings suggest that the presence of both high FLIPI score and high tumor burden defines a population with poorer prognosis than either factor alone. In supportive evidence from the literature, a FLIPI score of ≥3 has been associated with poor prognosis in terms of PFS and OS in a number of studies and analyses in both previously untreated and relapsed FL patients treated with various different regimens and modalities [7,9-11,30,31]. Similarly, the presence of a high tumor burden has been shown to be a significant poor prognostic factor [13]. As previously noted [28], there is no standard of care for relapsed FL, with various different approaches recommended as possible therapeutic options in guidelines from the European Society for Medical Oncology [32] and the US National Comprehensive Cancer Network [33], including rituximab-chemotherapy and rituximab maintenance.

Table 4 Safety profiles in high-risk FL patients (safety population)

| AE, n (%) | Bortezomib-rituximab(N=102) | Rituximab(N=98) |
|-----------|-----------------------------|-----------------|
| Any AE    | 97 (95)                     | 88 (90)         |
| Any related AE | 91 (89)             | 64 (65)         |
| Any rituximab-related AE | 70 (69)           | 64 (65)         |
| Any bortezomib-related AE | 85 (83)             | NA              |
| Any grade ≥3 AE | 52 (51)                  | 31 (32)         |
| Any serious AE | 22 (22)                  | 16 (16)         |
| Any related serious AE | 14 (14)               | 4 (4)           |
| AE leading to treatment withdrawal | 8 (8)               | 2 (2)           |
| Deaths due to AEs | 2 (2)                     | 1 (1)           |

Most common AEs

| AE, n (%) | All grades | Grade ≥3 |
|-----------|------------|----------|
| Diarrhea | 50 (49) | 8 (8) | 11 (11) | 0 |
| Pyrexia  | 30 (29) | 0 | 16 (16) | 1 (1) |
| Fatigue  | 24 (24) | 1 (1) | 10 (10) | 0 |
| Neutropenia | 21 (21) | 18 (18) | 11 (11) | 6 (6) |
| Nausea   | 19 (19) | 1 (1) | 11 (11) | 0 |
| Abdominal pain | 18 (18) | 2 (2) | 9 (9) | 1 (1) |
| Decreased appetite | 18 (18) | 0 | 4 (4) | 0 |
| Infections | 58 (57) | 16 (16) | 27 (28) | 7 (7) |
| Upper respiratory tract | 16 (16) | 3 (3) | 6 (6) | 1 (1) |
| Herpes zoster | 16 (16) | 4 (4) | 3 (3) | 1 (1) |
| Pneumonia | 6 (6) | 3 (3) | 4 (4) | 3 (3) |
| Peripheral edema | 15 (15) | 2 (2) | 13 (13) | 2 (2) |
| Asthenia | 15 (15) | 1 (1) | 11 (11) | 4 (4) |
| Vomiting | 15 (15) | 0 | 11 (11) | 2 (2) |
| Constipation | 15 (15) | 0 | 8 (8) | 0 |
| Peripheral sensory neuropathy | 15 (15) | 1 (1) | 0 | 0 |
| Dypsnea  | 13 (13) | 1 (1) | 10 (10) | 4 (4) |
| Anemia   | 12 (12) | 4 (4) | 12 (12) | 5 (5) |
| Thrombocytopenia | 12 (12) | 5 (5) | 8 (8) | 2 (2) |
| Leukopenia | 7 (7) | 3 (3) | 12 (12) | 2 (2) |

AE, adverse event; NA, not applicable.
Table includes the most commonly reported AEs (≥15% at any grade or ≥3% grade ≥ 3 in either arm).
However, there is no specific management strategy defined for FL patients with high FLIPI score and/or high tumor burden, and thus identifying treatment options offering relatively greater clinical benefit in patients with these poor prognostic factors is of interest.

It is important to note that, per protocol, none of the patients in LYM3001 were rituximab-refractory, another factor representing a high-risk, difficult-to-treat population. Nevertheless, non-clinical studies provide a rationale for the potential utility of the bortezomib-rituximab combination in this patient subset; some preclinical data suggest that addition of bortezomib might be useful for overcoming resistance in FL and for resensitizing patients to treatment, including rituximab [34-36].

Regarding the safety profiles of bortezomib-rituximab and rituximab alone in this subgroup analysis of patients with high-risk FL, our findings reflect those in the overall study population but with somewhat elevated rates of toxicity in these high-risk patients [28]. As would be expected, bortezomib-rituximab was associated with additional toxicity and rates of AEs were higher in the combination arm compared with the rituximab arm; however this did not affect treatment feasibility, with patients receiving a median of five cycles of treatment in both arms and a higher proportion completing all five planned cycles in the bortezomib-rituximab arm than in the rituximab arm. As reported previously [28], the addition of bortezomib to rituximab was associated with peripheral neuropathy AEs, with 15% of patients in the bortezomib-rituximab arm experiencing peripheral sensory neuropathy and 1% experiencing peripheral motor neuropathy; however, only one grade 3 AE of peripheral sensory neuropathy, was reported in these high-risk patients. As noted previously [28], this rate and severity of peripheral neuropathy appeared limited compared with previous reports in myeloma, which was likely associated with the use of a weekly, instead of a twice-weekly, bortezomib dosing regimen.

Conclusions
In conclusion, bortezomib-rituximab appears an effective regimen for the management of patients with relapsed FL, offering clinical benefit compared with rituximab alone in this high-risk subgroup of patients with the poor prognostic features of high FLIPI score (≥3) and high tumor burden. Further prospective validation of these findings is warranted; an Eastern Cooperative Oncology Group (ECOG) phase 2 study is currently investigating bendamustine-rituximab with or without bortezomib in patients with either high FLIPI score (≥3) or high tumor burden by GELF criteria (NCT01216683). Ongoing biomarker analyses of the LYM3001 study may enable identification of specific patient subgroups deriving greater benefit from bortezomib-rituximab versus rituximab treatment.

Methods
Patients and study design
The LYM3001 study design has been reported previously [28]. LYM3001 was conducted at 164 centers in 29 countries across Europe, the Americas, and Asia-Pacific [28]; patients were enrolled between April 10, 2006, and August 12, 2008, and clinical data cut-off was June 15, 2010. Patients aged ≥18 years were enrolled in the study if they met all of the following key inclusion criteria: grade 1/2 FL (WHO criteria [37]) with ≥1 measurable lesion; documented relapse or progression following prior therapy; rituximab-naïve or rituximab-sensitive (defined as a response to and TTP of ≥6 months with prior rituximab-containing therapy); ECOG performance status ≤2; and no active central nervous system lymphoma. Patients were excluded if they had grade ≥2 peripheral neuropathy or neuropathic pain, or clinical evidence of a transformation to an aggressive lymphoma, or had received prior bortezomib. Review boards at all participating institutions approved the study, which was conducted according to the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent.

Patients were randomized (1:1) to receive five 5-week cycles consisting of bortezomib 1.6 mg/m² on days 1, 8, 15, and 22, plus rituximab 375 mg/m² on days 1, 8, 15, and 22 in cycle 1 and on day 1 in cycles 2–5; or rituximab alone on the same schedule. Randomization was stratified by FLIPI score (0–1 [low], 2 [intermediate], ≥3 [high]), prior rituximab therapy (yes, no), time since last dose of anti-lymphoma therapy (≤1, >1 year), and geographical region (United States/Canada, European Union, rest of the world). Patients were assigned based on a computer-generated randomization schedule that was pre-prepared by the study sponsor, as previously described [28].

The primary endpoint of the study was PFS; the secondary endpoints included ORR, CR rate, DOR, TTP, 1-year OS rate, and safety/tolerability. TTNT and TFI were additional predefined endpoints of clinical benefit. As reported previously [28], preplanned efficacy analyses were conducted in patient subgroups defined according to age, sex, ethnic origin, FLIPI score, prior rituximab, prior lines of therapy, time since last dose of antilymphoma treatment, disease stage, and tumor burden.

Assessments
Patients’ FLIPI score and tumor burden were recorded at screening based on the respective constitutive clinical parameters. An independent radiology committee (IRC)
assessed tumor response and progression using modified International Working Group Response Criteria [38]. Computed tomography (CT) scans with contrast (plus magnetic resonance imaging [MRI] if required) were performed at baseline, and every 10 weeks during and following treatment until disease progression or death; bone marrow aspiration and biopsy were performed for confirmation of CR. Upon disease progression, patients were followed every 3 months for survival, and subsequent anti-lymphoma therapy was recorded. AEs were graded according to the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE) version 3.0.

Statistical analysis
For the overall LYM3001 study, the planned sample size was 670 patients (accrual of 676 patients achieved), and the target number of PFS events was 514 [28]. The study was analyzed early, after 440 PFS events, per Independent Data Monitoring Committee recommendations as the planned 514 events would probably have been unachievable within a reasonable timeframe due to very low ongoing accumulation of PFS events [28].

PFS, TTP, TTNT, and OS were analyzed in the ITT population, with distributions estimated using the Kaplan-Meier method. Unstratified log-rank tests were used for comparisons between the bortezomib-rituximab and rituximab arms for high-risk patients and for patients with high FLIPI score or high tumor burden (P-values <0.05 were considered statistically significant). A Cox regression model was used for estimation of HRs and 95% CIs. ORR, CR rate, and DOR were analyzed in the response-evaluable population, which included all patients who received at least one dose of study drug, had at least one measurable tumor mass at baseline, and had at least one post-baseline response assessment by IRC. DOR was analyzed by the Kaplan-Meier method. The safety population comprised all patients who received at least one dose of study drug. Statistical analyses were performed with SAS software, version 9.1.3. The LYM3001 study is registered with ClinicalTrials.gov, number NCT00312845.

Competing interests
PLZ: no competing interests to declare; NKK: no competing interests to declare; HW: no competing interests to declare; BG: no competing interests to declare; JW: research and travel grants, and lecture honoraria, Roche; AVH: no competing interests to declare; DC: no competing interests to declare; RB: consultancy, Celgene, Novartis, GSK; DLE: employment, Millennium Pharmaceuticals, Inc., stock ownership, Johnson & Johnson; PT: employment, Janssen, stock ownership, Johnson & Johnson; CE: employment, Janssen, stock ownership, Johnson & Johnson; EZ: employment, Janssen, stock ownership, Johnson & Johnson; YAE: employment; Janssen, stock ownership, Johnson & Johnson; BC: consulting fees/honoraria, travel support, Johnson & Johnson, consultancy, Roche, Amgen, Sanofi, Pfizer, Millennium Pharmaceuticals, Inc., Celgene, Pharmacyclics, MedImmune, and CTI.

Authors’ contributions
D-LE, PT, YAE, and BC were involved in the design of the study. PLZ, NKK, HW, BG, JW, AVH, PS, DC, RB, and BC recruited and treated patients for this study. PLZ, NKK, HW, BG, JW, AVH, PS, DC, RB, PT, CE, EZ, YAE, and BC were involved in data collection and collation. EZ did statistical analyses of the data. PLZ, D-LE, PT, CE, YAE, and BC were involved in interpreting the data. PLZ, PT, CE, EZ, YAE, and BC were involved in writing the draft of the report. All authors reviewed the draft manuscript and provided critical feedback. All authors reviewed and approved the final draft of the manuscript.

Financial support
This research was funded by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Millennium Pharmaceuticals, Inc.

Acknowledgments
The authors would like to acknowledge the writing support of Steve Hill of FireKite during the development of this publication, which was funded by Millennium Pharmaceuticals, Inc., and Janssen Global Services.

Author details
1. Institute of Hematology and Medical Oncology ‘L. & A. Seragnoli’, University of Bologna, Bologna, Italy. 2. Hematology, SP Botkin Moscow City Hospital, Moscow, Russia. 3. Medical Oncology, Medical University Cancer Hospital, Tianjin, China. 4. Hematology, Hospital Sao Lucas, Porto Alegro, Brazil. 5. Hematology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland. 6. Hematology, Hospital St Jan AV, Brugge, Belgium. 7. Medical Oncology, Institut Bergonié, Bordeaux, France. 8. Clinical Hematology, Hospital Clinico de Salamanca, Salamanca, Spain. 9. Medical Oncology & Hematology, Sunnybrook Regional Cancer Center, Toronto, Canada. 10. Clinical Development, Millennium Pharmaceuticals, Inc, Cambridge, MA, USA. 11. Oncology R&D, Janssen R&D, High Wycombe, UK. 12. Oncology R&D, Janssen R&D, Rantan, NJ, USA. 13. Hematology, Hospices Civils de Lyon, Lyon, France.

Received: 30 August 2012 Accepted: 18 October 2012 Published: 22 October 2012

References
1. Friedberg JW: Treatment of follicular non-Hodgkin’s lymphoma: the old and the new. Semin Hematol 2008, 45:S2–56.
2. Kenkre VP, Kahl BS: Follicular lymphoma: emerging therapeutic strategies. Expert Rev Hematol 2010, 3:485–495.
3. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Boudjelal R, Catalano V, Brice P, et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42–51.
4. Ghelmini M. Follicular lymphoma. Ann Oncol 2010, 21:vii151–vii153.
5. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera N, Rodriguez MA, Tsimberidou AM, Verstovsek S, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006, 24:1582–1589.
6. Federico M, Bellei M, Marchessi L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pilini S, Pulsoni A, Soubeyran P, et al: Follicular lymphoma international prognostic index 2: a new prognostic index for follicular
lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009, 27:4555–4562.

7. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JG, Rantza-Zaee R, Au WY, Belleri M, Brice P, Caballero D, et al: Follicular lymphoma international prognostic index. Blood, 2004, 104:1258–1265.

8. Luminari S, Colmee MC, Montanini A, Fedele M: Prognostic tools in follicular lymphoma. Expert Rev Hematol 2009, 2:549–556.

9. Solal-Celigny P, Cahu X, Cartron G: Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010, 92:246–254.

10. Montoto S, Lopez-Guillerme A, Altes A, Perea G, Feenier A, Casmos M, Villela L, Bosch F, Esteve J, Cervantes F, et al: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004, 15:1484–1489.

11. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G: Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol 2010, 122:193–199.

12. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednisomine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires, Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997, 15:1110–1117.

13. Morschhauser F, Jouvenier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Ferme C, Copin MC, Lamy T: Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d’Etude des Lymphomes de l’Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Cancer 2010, 116:4399–4408.

14. Fedele M, Vitolo U, Zinzani PL, Chiesi T, O’G, Bellesi G, Magagnoli M, Liberati M, Boccroni C, Nicola P, et al: Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases Intergroupo Italiano Linfomi. Blood 2000, 96:783–789.

15. Rueland J, Johnson NA, Fahnin P, Connors JM, Sehn LH, Gascoyne RD: Prognostic factors in follicular lymphoma. J Clin Oncol 2010, 28:2902–2913.

16. Rummel M: Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw 2010, 8:51–54.

17. Marcus R, Imre K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomas. J Clin Oncol 2008, 26:4579–4586.

18. Forstpointner R, Dreyling M, Repp R, Hermann S, Jehmlich N, Sebban C, Bouscoulas A, Metzner B, Pott C, Hartmann F, Rothmund F, Rohrbach R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, and mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 100:3064–3071.

19. Overman MJ, Feng L, Pro B, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, et al: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009, 27:5023–5030.

20. Chiappella A, Pigno P, Zinzani PL, Evangelista A, Fabbrini A, Fascetti F, Ferreri AJM, Franceschetti S, Frelione R, Gargantini L, et al: Weekly infusion of bortezomib in combination with rituximab in relapsed/refractory indolent non follicular and mantle cell lymphoma is safe and effective: two-years analysis of phase II trial BRIL06 of Intergroupo Italiano Linfomi (ILL) [abstract]. Blood 2010, 116:1617a.

21. Baocchi RA, Alnani L, Lustberg ME, In T, Porec P, Li X, Johnston JS, Byrd JC, Blum KA: Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011, 117:2442–2451.

22. Coffier F, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, De VS, et al: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011, 12:773–784.

23. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le G, Delmer A, Bordessolle D, Tilly H, Conmont B, et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the pretriumoxim era: effect of response quality on survival—a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2010, 28:822–829.

24. van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Sponroos DJ: Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009, 20:1697–1702.

25. Vose JM, Birman PJ, Lobenz RA, Lynch JC, Bociek GR, Weisenburger DD, Armitage JG: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index, Blood Marrow Transplant 2008, 14:36–42.

26. Dreyling M, Ghiehelimini M, Marcus R, Sailes G, Vitolo U: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22 Suppl 6:s59–v63.

27. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellani M, Byrd JC, Cauzcuz MS, Fayed LE, Glenn MI, et al: Non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2011, 9:484–560.

28. Czuczman MS, Olejniczak S, Gowda A, Kaur H, Knight AP, Starostik P, Deans J, Hernandez-Izalltuni FJ: Acquisition of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008, 14:1561–1570.

29. Jazireh AR, Vega M, Bonavida B: Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007, 67:1270–1281.

30. Vega MI, Martinez-Fanagia M, Jazireh AR, Huerta-Yepes S, Umezawa K, Martinez-Maza O, Bonavida B: The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitize rituximab-resistant AIDS-B non-Hodgkin’s lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008, 49:1892–1904.

31. Hanis NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Wardman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the
38. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.

doi:10.1186/1756-8722-5-67

Cite this article as: Zinzani et al: Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology & Oncology 2012 5:67.